Soligenix
Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing products to treat rare diseases with unmet medical needs. The company focuses on specialized biotherapeutics for orphan diseases and public health solutions for military and civilian applications, including vaccines and therapeutics for ricin exposure, Ebola, Marburg, and COVID-19. With expertise in orphan and unmet medical need indications, Soligenix conducts all of its Phase 2 and 3 clinical studies personally, ensuring high data quality and streamlined timelines.
Industries
Nr. of Employees
small (1-50)
Soligenix
29 Emmons Drive Suite B-10, Princeton, NJ 08540
Patents
Products
Topical photodynamic therapy for cutaneous T‑cell lymphoma (early-stage)
Visible‑light activated topical photodynamic therapy formulation evaluated in randomized Phase 3 studies for early‑stage cutaneous T‑cell lymphoma.
Topical therapy development for mild‑to‑moderate plaque psoriasis
Topical dermatologic therapeutic candidate for plaque psoriasis evaluated in the company pipeline.
Innate defense regulator immunomodulator for oral mucositis
Peptide‑based innate defense regulator technology developed to modulate host responses and reduce infection and mucositis in chemotherapy and radiation settings; progressed through preclinical studies and Phase 1 clinical testing.
Thermostable subunit vaccine for ricin exposure (thermostabilized formulation)
Subunit vaccine antigen formulations engineered for thermal stability and protective immunity in animal inhalational and systemic ricin exposure models.
Thermostabilization platform for vaccines
Platform technology for heat stabilization of vaccines to maintain epitope integrity and facilitate distribution without strict cold‑chain requirements.
Therapeutic candidates targeting bacterial infections and antibiotic resistance
Preclinical and early clinical therapeutic programs targeting antibiotic‑resistant and emerging bacterial infections.
Topical photodynamic therapy for cutaneous T‑cell lymphoma (early-stage)
Visible‑light activated topical photodynamic therapy formulation evaluated in randomized Phase 3 studies for early‑stage cutaneous T‑cell lymphoma.
Topical therapy development for mild‑to‑moderate plaque psoriasis
Topical dermatologic therapeutic candidate for plaque psoriasis evaluated in the company pipeline.
Innate defense regulator immunomodulator for oral mucositis
Peptide‑based innate defense regulator technology developed to modulate host responses and reduce infection and mucositis in chemotherapy and radiation settings; progressed through preclinical studies and Phase 1 clinical testing.
Thermostable subunit vaccine for ricin exposure (thermostabilized formulation)
Subunit vaccine antigen formulations engineered for thermal stability and protective immunity in animal inhalational and systemic ricin exposure models.
Thermostabilization platform for vaccines
Platform technology for heat stabilization of vaccines to maintain epitope integrity and facilitate distribution without strict cold‑chain requirements.
Therapeutic candidates targeting bacterial infections and antibiotic resistance
Preclinical and early clinical therapeutic programs targeting antibiotic‑resistant and emerging bacterial infections.
Services
Full-service conduct of Phase 2 and Phase 3 clinical studies with site engagement, specialized recruitment and protocol execution.
In-house project management and regulatory coordination to support development programs, filings and interactions with regulatory authorities.
Management of government‑funded R&D programs for biodefense and infectious disease applications, including compliance with agency requirements.
Access to and coordination of disease‑specific scientific advisory boards to inform clinical strategy and endpoint selection.
Full-service conduct of Phase 2 and Phase 3 clinical studies with site engagement, specialized recruitment and protocol execution.
In-house project management and regulatory coordination to support development programs, filings and interactions with regulatory authorities.
Management of government‑funded R&D programs for biodefense and infectious disease applications, including compliance with agency requirements.
Access to and coordination of disease‑specific scientific advisory boards to inform clinical strategy and endpoint selection.
Expertise Areas
- Clinical trial management
- Rare disease and orphan drug development
- Vaccine development and thermostabilization
- Photodynamic topical therapies for dermatology
Key Technologies
- Topical photodynamic therapy (visible-light activated)
- Innate defense regulator peptides (immunomodulatory peptides)
- Vaccine thermostabilization and lyophilization
- Subunit / recombinant vaccine antigens
News & Updates
Soligenix, Inc. (Nasdaq: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix announced positive results in treating cutaneous T-cell lymphoma (CTCL) patients with HyBryte™.
Soligenix announced a publication demonstrating that the CiVax™ booster induces rapid broad protection against COVID-19 variants.
Soligenix announced its recent accomplishments and financial results for the year 2024.
Results from the Phase 3 FLASH study on Hypericin ointment for CTCL.
A white paper discussing SGX301 as a treatment for early-stage CTCL.
Soligenix, Inc. (Nasdaq: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix announced positive results in treating cutaneous T-cell lymphoma (CTCL) patients with HyBryte™.
Soligenix announced a publication demonstrating that the CiVax™ booster induces rapid broad protection against COVID-19 variants.
Soligenix announced its recent accomplishments and financial results for the year 2024.
Results from the Phase 3 FLASH study on Hypericin ointment for CTCL.
A white paper discussing SGX301 as a treatment for early-stage CTCL.